(177)Lu-DOTATATE treatment in neuroendocrine tumours. A preliminary study
Irene Espallardo
Revista espanola de medicina nuclear e imagen molecular, 2016
View PDFchevron_right
Preparation of Therapeutic Dose of 177Lu-DOTA-TATE Using a Novel Single Vial Freeze-dried Kit: A Comparison with ‘In-situ’ Preparation at Hospital Radiopharmacy
Haladhar Dev Sarma
Current Radiopharmaceuticals, 2014
View PDFchevron_right
Semiautomated labelling and fractionation of yttrium-90 and lutetium-177 somatostatin analogues using disposable syringes and vials
Angelina Filice
Nuclear Medicine Communications, 2012
View PDFchevron_right
Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
Geoffrey Schembri
Asia Oceania Journal of Nuclear Medicine and Biology, 2015
View PDFchevron_right
{"__content__"=>"Guidance on Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division.", "sup"=>{"__content__"=>"177"}}
Eric Andersen
Journal of nuclear medicine technology, 2018
View PDFchevron_right
Production and quality control of [ 90 Y]DOTATOC for treatment of metastatic neuroendocrine tumors: results of 85 syntheses
Giordano Savelli
View PDFchevron_right
90Y/177Lu-DOTATOC: From Preclinical Studies to Application in Humans
Corrado Cittanti
Pharmaceutics
View PDFchevron_right
Single vial formulation for theranostic radiopharmaceutical preparation
Archana Mukherjee
Journal of Radioanalytical and Nuclear Chemistry, 2014
View PDFchevron_right
Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors
Martyn Caplin
The New England journal of medicine, 2017
View PDFchevron_right
Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
Amichay Meirovitz
The Journal of Nuclear Medicine, 2021
View PDFchevron_right
Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours
J. Müller-Brand
European Journal of Nuclear Medicine and Molecular Imaging, 2013
View PDFchevron_right
Methods for preparation and administration of lutetium-177 oxodotreotide 3.7 GBq: proceedings from an Italian advisory board
Cinzia Pettinato
Clinical and Translational Imaging, 2021
View PDFchevron_right
Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
Renata Mikołajczak, Jolanta Kunikowska
European Journal of Nuclear Medicine and Molecular Imaging, 2011
View PDFchevron_right
Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy
Arpit Mitra
Cancer Biotherapy and Radiopharmaceuticals
View PDFchevron_right
Formulation and evaluation of freeze-dried DOTMP kit for the preparation of clinical-scale 177Lu-DOTMP and 153Sm-DOTMP at the hospital radiopharmacy
Haladhar Dev Sarma
Radiochimica Acta, 2015
View PDFchevron_right
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Marta Cremonesi
European Journal of Nuclear Medicine and Molecular Imaging, 2011
View PDFchevron_right
{"__content__"=>"Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.", "sup"=>{"__content__"=>"177"}}
Orit Jacobson
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018
View PDFchevron_right
A 'mix-and-use' approach for formulation of human clinical doses of (177) Lu-DOTMP at hospital radiopharmacy for management of pain arising from skeletal metastases
AJIT SHINTO
Journal of labelled compounds & radiopharmaceuticals, 2017
View PDFchevron_right
External dose assessment from the patients treated by 177Lu-DOTATATE
Mohammad Deevband
2022
View PDFchevron_right
A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy
dominique delbeke
Endocrine-Related Cancer, 2021
View PDFchevron_right
177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials
Stefano Severi
Cancers
View PDFchevron_right
Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours
Monika Tomaszuk
Endokrynologia Polska
View PDFchevron_right
Preparation of Patient Doses of [ 177 Lu]Lu-DOTATATE and [ 177 Lu] Lu-PSMA-617 with Carrier Added (CA) and No Carrier Added (NCA) 177 Lu
Raviteja Nanabala, Pillai M.R.A.
View PDFchevron_right
Development and preclinical evaluations of therapeutic radiopharmaceuticals based on Lu-177 and Y-90 labeled monoclonal antibodies and peptides- Establishment and standardization of a technology for ready to use production of cold kit formulation of DOTA-Rituximab and peptide based radiopharmaceutic
Katarina Smilkov
2012
View PDFchevron_right
Chapter 9 Lutetium-177 production and radiopharmaceuticals development
Pillai M.R.A.
View PDFchevron_right
On the preparation of a therapeutic dose of 177Lu-labeled DOTA–TATE using indigenously produced 177Lu in medium flux reactor
Sharmila Banerjee
Applied Radiation and Isotopes, 2007
View PDFchevron_right
A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours
Jair Mengatti
Applied Radiation and Isotopes, 2009
View PDFchevron_right
177Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years’ experience from a tertiary cancer care centre in India
kumar kallur
View PDFchevron_right